The current treatment for drug-susceptible tuberculosis (TB) used in South Africa last for six months, effectively cures TB and is dirt cheap. Two studies in recent years have shown that TB can be cured in four or in some cases even two months, but price and other complications make these treatments tricky to implement. At a conference in Seattle last week, a major trial of an alternative four-month treatment reported disappointing findings. Elri Voigt unpacks the latest findings and asks what the prospects now are for shortening TB treatment.
Chimeric antigen receptors (CARs) have mainly been making headlines as a cutting-edge form of cancer treatment. Recently, however, presentations on CARs have been given at HIV conferences. Elri Voigt asks what CARs actually are and how they might one day be used to treat HIV.
Long-acting injections have been successfully used as contraception and more recently HIV prevention. Now researchers are exploring whether similar long-acting injections could be used for the prevention and treatment of tuberculosis. Tiyese Jeranji reports.
Broadly neutralising antibodies (bnAbs) are one of the most active and exciting areas in HIV research. Last year Spotlight reported on a “proof of concept” study showing that a specific bnAb can successfully prevent infection with certain strains of HIV. Now, we also have intriguing findings suggesting that bnAbs may have a role to play in the treatment of HIV in children. Elri Voigt reports.
There is no time to waste in planning the South African rollout of cabotegravir (CAB LA), the long-lasting antiretroviral injection approved for use in the United States in December 2021, say local health experts.